Airain Ltd’s Arcturus Therapeutics ARCT Stock Holding History

Airain Ltd’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,533	Closed	-$67K	–	788
2015 Q4	$67K	Buy	+1,533	New	+$69K	﹤0.01%	784

Other funds holding ARCT

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Airain Ltd's ARCT Position: Q1 2016 in Review

Airain Ltd sold out of Arcturus Therapeutics (ARCT) in Q1 2016, closing a stake of 1,533 shares — an estimated $67K sold.

Airain Ltd first reported a position in ARCT in Q4 2015 and held it in 1 quarter. The position peaked at $67K in Q4 2015. 46 funds tracked by Wall St. Rank hold ARCT as of Q1 2016.

Airain Ltd reported no remaining Arcturus Therapeutics position as of Q1 2016 after selling out during the quarter.
Airain Ltd sold 1,533 Arcturus Therapeutics shares in Q1 2016, an estimated $67K.
Airain Ltd first reported a position in Arcturus Therapeutics in Q4 2015 and held it in 1 quarter.
Airain Ltd's Arcturus Therapeutics position peaked at $67K in Q4 2015.
46 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2016.

Based on Airain Ltd's 13F filing for Q1 2016, filed 9 May 2016.